Pharmacological interventions in primary care: Hopes and Illusions

Frontiers of Neurology and Neuroscience

Volumn 24, Issue , 2009, Pages 54-65

  Assal, Frédéric ^a   Van Der Meulen, Marian ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; BENZODIAZEPINE; CARBAMAZEPINE; CHLORPROMAZINE; CHOLINESTERASE INHIBITOR; CITALOPRAM; CLOZAPINE; CYCLOOXYGENASE 2 INHIBITOR; DONEPEZIL; GABAPENTIN; GALANTAMINE; HALOPERIDOL; LORAZEPAM; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; RIVASTIGMINE; SERTRALINE; THIORIDAZINE; TRAZODONE; UNINDEXED DRUG; VALPROIC ACID;

AGITATION; AGRANULOCYTOSIS; ALZHEIMER DISEASE; AMNESIA; ANOREXIA; ANTIOXIDANT ACTIVITY; BRADYCARDIA; CARDIOVASCULAR RISK; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; CONFUSION; DIZZINESS; DROWSINESS; DRUG DEPENDENCE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; ESTROGEN THERAPY; EXTRAPYRAMIDAL SYMPTOM; FALLING; GASTROINTESTINAL SYMPTOM; HALLUCINATION; HEART BLOCK; HUMAN; LOW DRUG DOSE; META ANALYSIS; NAUSEA; NEUROPROTECTION; NEUROTRANSMISSION; PARADOXICAL DRUG REACTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; QT PROLONGATION; REVIEW; RISK FACTOR; SEDATION; SEROTONIN SYNDROME; SIDE EFFECT; SYSTEMATIC REVIEW; TREMOR; METHODOLOGY; PRIMARY HEALTH CARE;

ALZHEIMER DISEASE; CLINICAL TRIALS AS TOPIC; HUMANS; PRIMARY HEALTH CARE;

EID: 65349129579     PISSN: 16604431     EISSN: 16622804     Source Type: Book Series    
DOI: 10.1159/000197884     Document Type: Review

References (45)

1. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.
2. Assal F, Cummings JL: Neuropsychiatric symptoms in the dementias. Curr Opin Neurol 2002;15:445-450.
3. Whitehouse PJ, Price DL, Clark AW, Coyle JT, DeLong MR: Alzheimer disease: evidence for selective loss of cholinergic neurons in the nucleus basa-lis. Ann Neurol 1981;10:122-126.
4. Trinh NH, Hoblyn J, Mohanty S, Yaffe K: Efficacy of cholinesterase inhibitors in the treatment of neu-ropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis. J Am Med Assoc 2003; 289:210-216.
5. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT: A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology 1998;50:136-145.
6. Winblad B, Engedal K, Soininen H, Verhey F, Waldemar G, Wimo A, Wetterholm AL, Zhang R, Haglund A, Subbiah P: A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 2001;57:489-495.
7. Winblad B, Kilander L, Eriksson S, Minthon L, Batsman S, Wetterholm AL, Jansson-Blixt C, Haglund A: Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study. Lancet 2006;367:1057-1065.
8. Courtney C, Farrell D, Gray R, Hills R, Lynch L, Sellwood E, Edwards S, Hardyman W, Raftery J, Crome P, Lendon C, Shaw H, Bentham P: Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet 2004;363:2105-2115.
9. Sink KM, Holden KF, Yaffe K: Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. J Am Med Assoc 2005;293:596-608.
10. Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S, Galasko D, Jin S, Kaye J, Levey A, Pfeiffer E, Sano M, van Dyck CH, Thal LJ: Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 2005;352:2379-2388.
11. Wilcock GK, Lilienfeld S, Gaens E: Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group. Br Med J 2000;321:1445-1449.
12. Raskind MA, Peskind ER, Truyen L, Kershaw P, Damaraju CV: The cognitive benefits of galan-tamine are sustained for at least 36 months: a long-term extension trial. Arch Neurol 2004;61:252-256.
13. Mayor S: Regulatory authorities review use of galan-tamine in mild cognitive impairment. Br Med J 2005;330: 276.
14. Rosler M, Anand R, Cicin-Sain A, Gauthier S, Agid Y, Dal-Bianco P, Stahelin HB, Hartman R, Gharabawi M: Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. Br Med J 1999;318:633-638.
15. Winblad B, Grossberg G, Frolich L, Farlow M, Zechner S, Nagel J, Lane R: IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease. Neurology 2007;69: S14-S22.
16. Cummings JL: Use of cholinesterase inhibitors in clinical practice: evidence-based recommendations. Am J Geriatr Psychiatry 2003;11:131-145.
17. Howard RJ, Juszczak E, Ballard CG, Bentham P, Brown RG, Bullock R, Burns AS, Holmes C, Jacoby R, Johnson T, Knapp M, Lindesay J, O'Brien JT, Wilcock G, Katona C, Jones RW, DeCesare J, Rodger M: Donepezil for the treatment of agitation in Alzheimer's disease. N Engl J Med 2007;357:1382-1392.
18. Neumann PJ, Hermann RC, Kuntz KM, Araki SS, Duff SB, Leon J, Berenbaum PA, Goldman PA, Williams LW, Weinstein MC: Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease. Neurology 1999;52:1138-1145.
19. Parsons CG, Danysz W, Quack G: Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist - a review of preclini-cal data. Neuropharmacology 1999;38:735-767.
20. Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ: Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 2003;348:1333-1341.
21. Qaseem A, Snow V, Cross JT Jr, Forciea MA, Hopkins R Jr, Shekelle P, Adelman A, Mehr D, Schellhase K, Campos-Outcalt D, Santaguida P, Owens DK: Current pharmacologic treatment of dementia: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med 2008;148:370-378.
22. Gauthier S, Loft H, Cummings J: Improvement in behavioural symptoms in patients with moderate to severe Alzheimer's disease by memantine: a pooled data analysis. Int J Geriatr Psychiatry 2008;23:537-545.
23. Maidment ID, Fox CG, Boustani M, Rodriguez J, Brown RC, Katona CL: Efficacy of memantine on behavioral and psychological symptoms related to dementia: a systematic meta-analysis. Ann Pharmacother 2008;42:32-38.
24. Jones RW, Bayer A, Inglis F, Barker A, Phul R: Safety and tolerability of once-daily versus twice-daily memantine: a randomised, double-blind study in moderate to severe Alzheimer's disease. Int J Geriatr Psychiatry 2007;22:258-262.
25. Waldemar G, Hyvarinen M, Josiassen MK, Korner A, Lehto H, Wetterberg P: Tolerability of switching from donepezil to memantine treatment in patients with moderate to severe Alzheimer's disease. Int J Geriatr Psychiatry 2008;23:979-981.
26. Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I: Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. J Am Med Assoc 2004;291:317-324.
27. Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, Woodbury P, Growdon J, Cotman CW, Pfeiffer E, Schneider LS, Thal LJ: A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N Engl J Med 1997;336:1216-1222.
28. Ramassamy C, Longpre F, Christen Y: Ginkgo biloba extract (EGb 761) in Alzheimer's disease: is there any evidence? Curr Alzheimer Res 2007;4:253-262.
29. Henderson VW: Estrogen-containing hormone therapy and Alzheimer's disease risk: understanding discrepant inferences from observational and experimental research. Neuroscience 2006;138: 1031-1039.
30. Rapp SR, Espeland MA, Shumaker SA, Henderson VW, Brunner RL, Manson JE, Gass ML, Stefanick ML, Lane DS, Hays J, Johnson KC, Coker LH, Dailey M, Bowen D: Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. J Am Med Assoc 2003; 289:2663-2672.
31. McGeer PL, McGeer EG: NSAIDs and Alzheimer disease: epidemiological, animal model and clinical studies. Neurobiol Aging 2007;28:639-647.
32. Bentham P, Gray R, Sellwood E, Hills R, Crome P, Raftery J: Aspirin in Alzheimer's disease (AD2000): a randomised open-label trial. Lancet Neurol 2008; 7:41-49.
33. Zhou B, Teramukai S, Fukushima M: Prevention and treatment of dementia or Alzheimer's disease by statins: a meta-analysis. Dement Geriatr Cogn Disord 2007;23:194-201.
34. McGuinness B, Todd S, Passmore P, Bullock R: The effects of blood pressure lowering on development of cognitive impairment and dementia in patients without apparent prior cerebrovascular disease. Cochrane Database Syst Rev 2006:CD004034.
35. Schneider LS, Tariot PN, Dagerman KS, Davis SM, Hsiao JK, Ismail MS, Lebowitz BD, Lyketsos CG, Ryan JM, Stroup TS, Sultzer DL, Weintraub D, Lieberman JA: Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med 2006;355:1525-1538.
36. Schneider LS, Dagerman KS, Insel P: Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. J Am Med Assoc 2005;294: 1934-1943.
37. Assal F, Alarcon M, Solomon EC, Masterman D, Geschwind DH, Cummings JL: Association of the serotonin transporter and receptor gene polymorphisms in neuropsychiatric symptoms in Alzheimer disease. Arch Neurol 2004;61:1249-1253.
38. Assal F, Cummings JL: Neuropathological changes underlying neuropsychiatric symptoms on Alzheimer's disease; in Gauthier S, Cummings JL (eds): Alzheimer's Disease and Related Disorders Annual 2002. London, Martin Dunitz, 2002, pp 199-215.
39. Nyth AL, Gottfries CG: The clinical efficacy of cit-alopram in treatment of emotional disturbances in dementia disorders. A Nordic multicentre study. Br J Psychiatry 1990;157:894-901.
40. Lyketsos CG, Sheppard JM, Steele CD, Kopunek S, Steinberg M, Baker AS, Brandt J, Rabins PV: Randomized, placebo-controlled, double-blind clinical trial of sertraline in the treatment of depression complicating Alzheimer's disease: initial results from the Depression in Alzheimer's Disease study. Am J Psychiatry 2000;157:1686-1689.
41. Bains J, Birks JS, Dening TR: The efficacy of antide-pressants in the treatment of depression in dementia. Cochrane Database Syst Rev 2002:CD003944.
42. Taragano FE, Lyketsos CG, Mangone CA, Allegri RF, Comesana-Diaz E: A double-blind, randomized, fixed-dose trial of fluoxetine vs. amitriptyline in the treatment of major depression complicating Alzheimer's disease. Psychosomatics 1997;38:246-252.
43. Cummings JL, Doody R, Clark C: Disease-modifying therapies for Alzheimer disease: challenges to early intervention. Neurology 2007;69: 1622-1634.
44. Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, Eisner L, Kirby L, Rovira MB, Forette F, Orgogozo JM: Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005;64:1553-1562.
45. Assal F, Allali G, Kressig RW, Herrmann FR, Beauchet O: Galantamine improves gait performance in patients with Alzheimer's disease. J Am Geriatr Soc 2008;56:946-947.